BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cerilliant
Citi
Queensland Health
Farmers Insurance
Covington
Merck
McKinsey
Chubb
Accenture
Deloitte

Generated: January 20, 2018

DrugPatentWatch Database Preview

Oak Pharms Inc Company Profile

« Back to Dashboard

What is the competitive landscape for OAK PHARMS INC, and when can generic versions of OAK PHARMS INC drugs launch?

OAK PHARMS INC has six approved drugs.

There are seven US patents protecting OAK PHARMS INC drugs on OAK PHARMS INC drugs in the past three years.

There are sixty-six patent family members on OAK PHARMS INC drugs in twenty-two countries and thirteen supplementary protection certificates in ten countries.

Summary for Oak Pharms Inc
International Patents:66
US Patents:7
Tradenames:6
Ingredients:5
NDAs:6

Drugs and US Patents for Oak Pharms Inc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Oak Pharms Inc ZIOPTAN tafluprost SOLUTION/DROPS;OPHTHALMIC 202514-001 Feb 10, 2012 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Oak Pharms Inc COSOPT dorzolamide hydrochloride; timolol maleate SOLUTION/DROPS;OPHTHALMIC 020869-001 Apr 7, 1998 AT RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Oak Pharms Inc AZASITE azithromycin SOLUTION/DROPS;OPHTHALMIC 050810-001 Apr 27, 2007 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Oak Pharms Inc XOPENEX levalbuterol hydrochloride SOLUTION;INHALATION 020837-003 Jan 30, 2002 AN RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Oak Pharms Inc XOPENEX levalbuterol hydrochloride SOLUTION;INHALATION 020837-001 Mar 25, 1999 AN RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Oak Pharms Inc BETIMOL timolol SOLUTION/DROPS;OPHTHALMIC 020439-002 Mar 31, 1995 AT RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Oak Pharms Inc XOPENEX levalbuterol hydrochloride SOLUTION;INHALATION 020837-001 Mar 25, 1999 AN RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Oak Pharms Inc AZASITE azithromycin SOLUTION/DROPS;OPHTHALMIC 050810-001 Apr 27, 2007 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Oak Pharms Inc BETIMOL timolol SOLUTION/DROPS;OPHTHALMIC 020439-001 Mar 31, 1995 AT RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Oak Pharms Inc XOPENEX levalbuterol hydrochloride SOLUTION;INHALATION 020837-002 Mar 25, 1999 AN RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for Oak Pharms Inc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Oak Pharms Inc BETIMOL timolol SOLUTION/DROPS;OPHTHALMIC 020439-001 Mar 31, 1995 ➤ Subscribe ➤ Subscribe
Oak Pharms Inc XOPENEX levalbuterol hydrochloride SOLUTION;INHALATION 020837-003 Jan 30, 2002 ➤ Subscribe ➤ Subscribe
Oak Pharms Inc AZASITE azithromycin SOLUTION/DROPS;OPHTHALMIC 050810-001 Apr 27, 2007 ➤ Subscribe ➤ Subscribe
Oak Pharms Inc XOPENEX levalbuterol hydrochloride SOLUTION;INHALATION 020837-003 Jan 30, 2002 ➤ Subscribe ➤ Subscribe
Oak Pharms Inc XOPENEX levalbuterol hydrochloride SOLUTION;INHALATION 020837-004 Jul 18, 2003 ➤ Subscribe ➤ Subscribe
Oak Pharms Inc COSOPT dorzolamide hydrochloride; timolol maleate SOLUTION/DROPS;OPHTHALMIC 020869-001 Apr 7, 1998 ➤ Subscribe ➤ Subscribe
Oak Pharms Inc COSOPT dorzolamide hydrochloride; timolol maleate SOLUTION/DROPS;OPHTHALMIC 020869-001 Apr 7, 1998 ➤ Subscribe ➤ Subscribe
Oak Pharms Inc BETIMOL timolol SOLUTION/DROPS;OPHTHALMIC 020439-002 Mar 31, 1995 ➤ Subscribe ➤ Subscribe
Oak Pharms Inc XOPENEX levalbuterol hydrochloride SOLUTION;INHALATION 020837-002 Mar 25, 1999 ➤ Subscribe ➤ Subscribe
Oak Pharms Inc XOPENEX levalbuterol hydrochloride SOLUTION;INHALATION 020837-001 Mar 25, 1999 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for OAK PHARMS INC drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Ophthalmic Solution 0.0015% ➤ Subscribe 2/10/2016
➤ Subscribe Inhalation Aerosol 0.045 mg/actuation ➤ Subscribe 2/27/2012
➤ Subscribe Ophthalmic Solution 1% ➤ Subscribe 3/3/2011
➤ Subscribe Inhalation Solution 0.0025 ➤ Subscribe 5/23/2006
➤ Subscribe Ophthalmic Solution 2%/0.5% ➤ Subscribe 10/11/2005
➤ Subscribe Inhalation Solution 0.0103%, 0.021% and 0.042% ➤ Subscribe 6/20/2005

Non-Orange Book US Patents for Oak Pharms Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,749,970 Topical treatment of prevention of ocular infections ➤ Subscribe
5,985,920 Difluoroprostaglandin derivatives and their use ➤ Subscribe
6,685,958 Quinolone carboxylic acid compositions and related methods of treatment ➤ Subscribe
7,732,415 Topical treatment or prevention of ocular infections ➤ Subscribe
6,699,492 Quinolone carboxylic acid compositions and related methods of treatment ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for Oak Pharms Inc Drugs

Supplementary Protection Certificates for Oak Pharms Inc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
90041 Netherlands ➤ Subscribe PRODUCT NAME: DORZOLAMIDE, DESGEWENST IN DE VORM VAN EEN OFTALMOLOGISCH AAN- VAARDBAAR ZOUT, EN TIMOLOL, DESGEWENST IN DE VORM VAN EEN OFTAL -MOLOGISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER DORZOLLAMIDEHY- DROCHLORIDE EN TIMOLOLMALEAAT, EEN EN ANDER ZODANIG DAT 0,05; NATL REGISTRATION NO/DATE: VG 22871 19980805; FIRST REGISTRATION: DK 19045 19980306
943 Luxembourg ➤ Subscribe 91943, EXPIRES: 20221222
0407 Netherlands ➤ Subscribe 300407, 20171222, EXPIRES: 20221221
00C/001 Belgium ➤ Subscribe PRODUCT NAME: DORZOLAMIDI HYDROCHLORIDUM EQ. DORZOLAMIDUM, TIMOLOLI MALEAS EQ. TIMOLOLUM; NAT. REGISTRATION NO/DATE: 922 IS 180 F 13 19981110; FIRST REGISTRATION: DK 19045 19980306
9 Finland ➤ Subscribe
2008 00041 Denmark ➤ Subscribe
C0020 France ➤ Subscribe PRODUCT NAME: TAFLUPROST; REGISTRATION NO/DATE IN FRANCE: CIS:6 000 728 O DU 20110328; REGISTRATION NO/DATE AT EEC: 43230 DU 20080430
C013/2011 Ireland ➤ Subscribe SPC013/2011: 20110808, EXPIRES: 20221221
C/GB99/043 United Kingdom ➤ Subscribe PRODUCT NAME: DORZOLAMIDE OR AN OPHTHALMOLOGICALLY ACCEPTABLE SALT THEREOF, PREFERABLY DORZOLAMIDE HYDROCHOLORIDE, PLUS TIMOLOL OR AN OPHTHAMOLOGICALLY ACCEPTABLE SALT THEREOF, PREFERABLY TIMOLOL MALEATE; REGISTERED: DK 19045 19980306; UK PL 00025/0373 19980804
C/GB09/005 United Kingdom ➤ Subscribe PRODUCT NAME: TAFLUPROST OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: DK 43230 20080430; UK PL 16058/0011-0001 20081017
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Fish and Richardson
QuintilesIMS
Farmers Insurance
Teva
Colorcon
Federal Trade Commission
Argus Health
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot